—In a recent study, French survivors of non-Hodgkin lymphoma (NHL) reported significant physical impairments, emotional distress, and relationship issues, raising new questions about their future care ...

Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma. Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 ...

Incyte (($INCY)) announced an update on their ongoing clinical study. Incyte Corporation is currently conducting a study titled realMIND: A ...

Diffuse large B cell lymphoma (DLBCL) is a prevalent subtype of non-Hodgkins lymphoma and can occasionally present as a rare and aggressive testicular variant. This case presents a middle-aged male ...

By analyzing the tumor environment of diffuse large B-cell lymphoma (DLBCL), researchers from The University of Texas MD ...

Jeremy S Abramson and colleagues reported that glofitamab plus gemcitabine and oxaliplatin (GemOx) significantly improved overall survival (OS) in transplant-ineligible patients with relapsed or ...

How Can Biomarkers Help Individualize Treatment of Diffuse Large B-cell Lymphoma? Using Biomarkers to Diagnose Diffuse Large B-cell Lymphoma ...

Epidemiology, clinical outcomes, and healthcare resource utilization in non-Hodgkin’s lymphoma patients with protein-energy malnutrition hospitalized for acute congestive heart failure: A ...

waveLINE-010: Zilovertamab vedotin plus R-CHP versus R-CHOP in untreated diffuse large B-cell lymphoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

Neuroscientist Gerald Voelbel’s journey from mysterious symptoms to a rare cancer and neurological disorder diagnosis highlights the power of self-advocacy and finding purpose.